FDA Approves Clinical Trial of TDI-132 (Gilenya) in ALS Patients
CAMBRIDGE, Mass., Feb. 11, 2013 /PRNewswire-USNewswire/ -- The
ALS Therapy Development Institute (ALS TDI) announced today that it
has received FDA approval to conduct a clinical trial of TDI-132
(aka: fingolimod, Gilenya™) in ALS.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2013 Category: Pharmaceuticals Source Type: news
Direct Healthcare Professional Communication: Refined guidance on when first dose monitoring procedures should be repeated for Gilenya (fingolimod)
Source: Novartis
Area: News
It is known that the effects of fingolimod on heart rate and atrioventricular conduction may recur on reintroduction of fingolimod (Gilenya) treatment following interruption. Further analyses of clinical pharmacology and dose titration data indicate that the risk of occurrence of these effects depends upon the duration of the interruption and time since initiation of treatment. In April 2012, Novartis issued notification about enhanced first dose monitoring procedures in relation to the transient decrease in heart rate and atrioventricular conduction delay upon treatment initiation with fingol...
Source: NeLM - News - February 7, 2013 Category: Drugs & Pharmacology Source Type: news
MHRA Drug Safety Update: repeat enhanced cardiovascular monitoring when restarting fingolimod (GilenyaT) after treatment interruption
Source: MHRA
Area: Evidence > Medication Safety
The January issue of the MHRA's Drug Safety Update has highlighted the risk of bradycardia and heart block on starting fingolimod treatment, or re-starting fingolimod after treatment interruption which can be minimised through enhanced cardiac monitoring.
The MHRA has updated its advice on enhanced cardiac monitoring on the basis of new clinical pharmacology analyses and dose titration data. Please see link below for full details. (Source: NeLM - Patient Safety)
Source: NeLM - Patient Safety - January 30, 2013 Category: Drugs & Pharmacology Source Type: news
Colitis-Associated Cancer May One Day Be Treated With Multiple Sclerosis Drug
After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC). The study, published online in the journal Cancer Cell, was led by Sarah Spiegel, Ph.D., Mann T. and Sara D... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 11, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news
Multiple sclerosis drug may one day treat colorectal cancer
(Virginia Commonwealth University) After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 9, 2013 Category: Global & Universal Source Type: news
Fingolimod in Scotland
The first person in Scotland to receive fingolimod (Gilenya) has started treatment. Fingolimod was approved in Scotland in September.
John O'Groats Journal
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - January 7, 2013 Category: Neurology Source Type: news
